
FASN Inhibitor – TVB-2640
Indication – NASH
Phase 2
FASN Inhibitor – TVB-2640
Indication – Oncology
Phase 2
FASN Inhibitor – TVB-3567
Indication – Undisclosed
Preclinical
Posters & Publications
A baseline signature of metabolites involving the gut-liver axis predicts MRI-PDFF response to FASN inhibitor TVB-2640 in NASH patients: results from the FASCINATE-1 study
EASL International Liver Congress
Read More